Henlius Has Denosumab Application Accepted In China
NMPA Also Currently Reviewing Adalimumab And Trastuzumab Filings
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
You may also be interested in...
Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.
In an exclusive interview with Generics Bulletin, Dr. Scott Liu, co-founder, and CEO of Chinese biosimilars and biologics specialist Shanghai Henlius Biotech, has set out his vision for the firm’s future in China and around the globe.
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.